Darunavir Patent Expiration
Darunavir is Used for treating HIV infection in both adult and pediatric patients. It was first introduced by Janssen Products Lp
Darunavir Patents
Given below is the list of patents protecting Darunavir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Prezista |
US7700645 (Pediatric) | Pseudopolymorphic forms of a HIV protease inhibitor | Jun 26, 2027 | Janssen Prods |
| Prezista | US7700645 | Pseudopolymorphic forms of a HIV protease inhibitor | Dec 26, 2026 | Janssen Prods |
| Prezista |
US8518987 (Pediatric) | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug 16, 2024
(Expired) | Janssen Prods |
| Prezista | US8518987 | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb 16, 2024
(Expired) | Janssen Prods |
| Prezista |
US7470506 (Pediatric) | Fitness assay and associated methods |
Dec 23, 2019
(Expired) | Janssen Prods |
| Prezista |
US8597876 (Pediatric) | Method of treating HIV infection |
Dec 23, 2019
(Expired) | Janssen Prods |
| Prezista |
US9889115 (Pediatric) | Fitness assay and associated methods |
Dec 23, 2019
(Expired) | Janssen Prods |
| Prezista | US7470506 | Fitness assay and associated methods |
Jun 23, 2019
(Expired) | Janssen Prods |
| Prezista | US8597876 | Method of treating HIV infection |
Jun 23, 2019
(Expired) | Janssen Prods |
| Prezista | US9889115 | Fitness assay and associated methods |
Jun 23, 2019
(Expired) | Janssen Prods |
| Prezista |
USRE43596 (Pediatric) | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Nov 09, 2017
(Expired) | Janssen Prods |
| Prezista | USRE43596 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
May 09, 2017
(Expired) | Janssen Prods |
| Prezista |
USRE42889 (Pediatric) | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Apr 19, 2017
(Expired) | Janssen Prods |
| Prezista |
USRE43802 (Pediatric) | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Apr 19, 2017
(Expired) | Janssen Prods |
| Prezista |
US6037157 (Pediatric) | Method for improving pharmacokinetics |
Dec 26, 2016
(Expired) | Janssen Prods |
| Prezista |
US6703403 (Pediatric) | Method for improving pharmacokinetics |
Dec 26, 2016
(Expired) | Janssen Prods |
| Prezista | USRE42889 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Oct 19, 2016
(Expired) | Janssen Prods |
| Prezista | USRE43802 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Oct 19, 2016
(Expired) | Janssen Prods |
| Prezista | US6037157 | Method for improving pharmacokinetics |
Jun 26, 2016
(Expired) | Janssen Prods |
| Prezista | US6703403 | Method for improving pharmacokinetics |
Jun 26, 2016
(Expired) | Janssen Prods |
| Prezista |
US5843946 (Pediatric) | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Jun 01, 2016
(Expired) | Janssen Prods |
| Prezista | US5843946 | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Dec 01, 2015
(Expired) | Janssen Prods |
| Prezista |
US6248775 (Pediatric) | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Feb 13, 2015
(Expired) | Janssen Prods |
| Prezista | US6248775 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Aug 13, 2014
(Expired) | Janssen Prods |
| Prezista |
US6335460 (Pediatric) | α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors |
Feb 25, 2013
(Expired) | Janssen Prods |
| Prezista | US6335460 | α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors |
Aug 25, 2012
(Expired) | Janssen Prods |
Darunavir's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List